Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Acelyrin Inc (SLRN)

Acelyrin Inc (SLRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases GlobeNewswire - Tue May 13, 2025

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
Alumis Stockholders Approve Merger with ACELYRIN GlobeNewswire - Tue May 13, 2025

Alumis Stockholders Approve Merger with ACELYRIN...

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
Alumis Stockholders Approve Merger with ACELYRIN GlobeNewswire - Tue May 13, 2025

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases GlobeNewswire - Tue May 13, 2025

LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis GlobeNewswire - Tue May 6, 2025

ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today...

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis GlobeNewswire - Tue May 6, 2025

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis GlobeNewswire - Thu May 1, 2025

Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS...

SLRN : 2.27 (+1.79%)
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis GlobeNewswire - Thu May 1, 2025

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
Alumis and ACELYRIN Announce Amended Merger Agreement GlobeNewswire - Mon Apr 21, 2025

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
Alumis and ACELYRIN Announce Amended Merger Agreement GlobeNewswire - Mon Apr 21, 2025

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)

Barchart Exclusives

Apple Was Always 1 Step Behind in AI. In Chipmaking, It’s Now 1 Step Ahead. Barchart - Sat Aug 29, 3:30PM CDT
Apple beat rivals to a 2nm chip with the M6, betting AI's future runs on your device rather than the cloud. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.